ADX-629 for Chronic Cough
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the safety and effectiveness of a new oral treatment called ADX-629 for individuals with chronic cough. Chronic cough is a persistent cough that persists without explanation by other lung issues. Participants will receive either ADX-629 tablets or a placebo (a pill with no active medication) twice daily for 14 days. This trial may suit adults with a stubborn chronic cough not explained by other conditions and who do not smoke. Participants must stop using cough medicines during the trial. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important medical advancements.
Will I have to stop taking my current medications?
The trial requires you to stop taking antitussive medications (cough suppressants) for the duration of the study. If you are currently taking an ACE inhibitor, you must have stopped it at least 3 months before the screening.
Is there any evidence suggesting that ADX-629 is likely to be safe for humans?
Research has shown that ADX-629 is generally safe for people. In earlier studies, neither ADX-629 nor a placebo (a harmless pill with no active drug) raised major safety concerns. People taking ADX-629 did not experience more side effects than those taking the placebo. Another study suggested that ADX-629 might help reduce certain types of inflammation, offering protective benefits. Overall, the evidence so far indicates that ADX-629 is safe to use, with no major negative effects reported.12345
Why do researchers think this study treatment might be promising for chronic cough?
Unlike standard treatments for chronic cough, which often include cough suppressants and antihistamines, ADX-629 is unique because it targets the underlying inflammation that can cause persistent coughing. This treatment works by modulating the immune response, potentially reducing inflammation more effectively than current options. Researchers are excited about ADX-629 because it could offer faster relief and address the root cause of chronic cough, providing a new avenue for patients who haven't found success with existing treatments.
What evidence suggests that ADX-629 might be an effective treatment for chronic cough?
Research has shown that ADX-629, a type of medication, has potential in treating various conditions by reducing inflammation. Studies found that ADX-629 significantly improved liver function in patients with liver issues. By lowering certain levels in the body, ADX-629 may help reduce inflammation, a major problem in chronic cough. Although limited data exists specifically for chronic cough, the mechanism of ADX-629 suggests it could be effective. Early results from other trials indicate it might help conditions involving excessive inflammation. Participants in this trial will receive either ADX-629 or a placebo to further evaluate its effectiveness.26789
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Period 1
Participants receive either ADX-629 or placebo orally twice a day for 14 days
Washout
A washout period between treatment periods to clear the drug from the system
Treatment Period 2
Participants crossover to receive the alternate treatment (ADX-629 or placebo) for 14 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ADX-629
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aldeyra Therapeutics, Inc.
Lead Sponsor